Eculizumab and drug-induced haemolytic-uraemic syndrome

Clinical Kidney Journal

Volumn 6, Issue 5, 2013, Pages 484-485

  Faguer, Stanislas ^a   Huart, Antoine ^a   Frémeaux Bacchi, Véronique ^b   Ribes, David ^a   Chauveau, Dominique ^a  

^a CHU RANGUEIL   (France)

^b HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

drugs; eculizumab; haemolytic uraemic syndrome

Indexed keywords

CREATININE; ECULIZUMAB; LACTATE DEHYDROGENASE; MITOMYCIN;

ARTICLE; BREAST METASTASIS; CASE REPORT; CREATININE BLOOD LEVEL; DRUG RESPONSE; FEMALE; FOLLOW UP; GENETIC SCREENING; HEMATOLOGICAL PARAMETERS; HEMODIALYSIS; HEMOLYTIC UREMIC SYNDROME; HUMAN; KIDNEY FUNCTION; LACTATE DEHYDROGENASE BLOOD LEVEL; OUTCOME ASSESSMENT; PLASMAPHERESIS; PRIORITY JOURNAL; THROMBOCYTE COUNT; TREATMENT DURATION; TREATMENT FAILURE;

EID: 84885045257     PISSN: 20488505     EISSN: 20488513     Source Type: Journal    
DOI: 10.1093/ckj/sft078     Document Type: Article

References (4)

1. Gruppo RA, Rother RP. Eculizumab for congenital atypical hemolytic-uremic syndrome. N Engl J Med 2009; 360: 544-546
2. Lapeyraque AL, Malina M, Fremeaux-Bacchi V et al. Eculizumab in severe Shiga-toxin-associated HUS. N Engl J Med 2011; 364: 2561-2563
3. Nurnberger J, Philipp T, Witzke O et al. Eculizumab for atypical hemolytic-uremic syndrome. N Engl J Med 2009; 360: 542-544
4. Mistry B, Kimmel PL, Hetzel PC et al. The role of circulating immune complexes and biocompatibility of staphylococcal protein A immunoadsorption in mitomycin C-induced hemolytic uremic syndrome. Am J Kidney Dis 2004; 44: e50-e58